215 related articles for article (PubMed ID: 35571672)
1. Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report.
Li Z; Zhang B; Yang F; Yang L
Transl Cancer Res; 2022 Apr; 11(4):973-979. PubMed ID: 35571672
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
[TBL] [Abstract][Full Text] [Related]
4. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
7. Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited-stage small-cell lung cancer.
Lu M; Zhang R; Qi LS; Wang YL; Sun XX; You J
Thorac Cancer; 2022 Nov; 13(22):3208-3216. PubMed ID: 36208136
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
10. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
[TBL] [Abstract][Full Text] [Related]
14. Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
Ishida M; Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Takemura Y; Yamada T; Kanda H; Iwasaku M; Tokuda S; Kim YH; Takayama K
JTO Clin Res Rep; 2023 Apr; 4(4):100493. PubMed ID: 37025120
[TBL] [Abstract][Full Text] [Related]
15. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
Wu Y; Zhang T; Liu Y; Wang J; Bi N
Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
[TBL] [Abstract][Full Text] [Related]
17. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Jett JR; Schild SE; Kesler KA; Kalemkerian GP
Chest; 2013 May; 143(5 Suppl):e400S-e419S. PubMed ID: 23649448
[TBL] [Abstract][Full Text] [Related]
18. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
19. Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):658-666. PubMed ID: 30007803
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Hiranuma O; Yamada T; Kanda H; Nakano T; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
JTO Clin Res Rep; 2022 Jul; 3(7):100353. PubMed ID: 35789793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
